【佳学基因检测】Onc 基因和其他癌症化疗的新靶点的基因检测

基因治疗肿瘤要多少钱—争论

与同行交流时肿瘤启动预防及反复抑制基因检测发现《J Cancer Res Clin Oncol》在. 1984;107(1):1-14.发表了一篇题目为《Onc 基因和其他癌症化疗的新靶点的基因检测》肿瘤靶向药物治疗基因检测临床研究文章。该研究由H Busch等完成。详细讨论了原癌基因、癌变基因与肿瘤致病基因与普通看家基因检测中的区别，列出了基因检测机构基因检测项目选择的一个参考意见。

肿瘤靶向药物及正确治疗临床研究内容关键词：

Onc基因,化疗,新靶点,生存关联性,基因检测

肿瘤靶向治疗基因检测临床应用结果

分子生物学的贼新进展库肿瘤科癌症患者带来了希望，即对人类癌症的理解可能会迅速发展，并且可能会导致治疗的改进。随着基因克隆、DNA序列分析和改进的杂交方法的发展，尤其是基因解码技术在确解基因突变序列方面的突出优势，有可能评估癌症是否由基因剂量的改变、基因的点或多重突变、易位、缺失、插入、倒位、顺式或反式改变的启动子引起，或者是由扩增和各种其他遗传因素，包括改变特定 mRNA 种类读出率的增强子元素。 “Onc 基因”正在深入研究，因为它们提供了可管理的探针来评估这些各种可能性，还因为对其细胞类似物的研究可能会进一步了解正常胎儿和恶性细胞的分子生物学。尽管该领域的一些支持者过于热情，批评者也持否定态度，但很明显，分析工具和新信息将在进一步研究实验性癌症时具有价值，无论是否细胞癌基因（c-onc 基因）是否与人类癌症有关。与此同时，对参与生长过程的酶、蛋白质和表位的研究，为通过定量减少生物合成反应来抑制人类癌症开辟了新途径。

肿瘤发生与反复转移国际数据库描述：

Recent advances in molecular biology have raised the hope that understanding of human cancer might progress rapidly and that improvements in therapy might result (Bishop 1983a, b; Busch 1962; Busch 1976; Duesberg 1983). With the development of gene cloning, DNA sequence analysis and improved hybridization methods, it became possible to evaluate whether cancer results from alteration in gene dosage, point or multiple mutation of genes, translocations, deletions, insertions, inversions, cis or trans altered promoters, amplification, and a variety of other genetic factors, including enhancer elements that alter rates of readouts of particular mRNA species. "Onc genes" are under intensive study because they offer manageable probes for evaluation of these various possibilities and also because the study of their cellular analogs may further understanding of the molecular biology of normal fetal and malignant cells. Despite the excessive enthusiasm of some proponents of this field and the negativism of its critics (Bishop 1983 a, b; Duesberg 1983), it is clear that analytical tools and new information will be of value in further studies on experimental cancer, regardless of whether cellular oncogenes (c-onc genes) have anything to do with human cancer or not. In the meantime, studies on enzymes, proteins and epitopes involved in growth processes, have opened new avenues for inhibition of human cancer by quantitative reduction of biosynthetic reactions.